Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Niagen Bioscience, Inc. amended revolving credit of up to $10.0 million with Western Alliance Bank at 8.25% per year maturing November 12, 2025.
- Instrument
- revolving credit
- Principal
- up to $10.0 million
- Counterparty
- Western Alliance Bank
- Rate
- 8.25% per year
- Maturity
- November 12, 2025
- Event
- amendment
Exact text from the filing
the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”). The Credit Agreement provides for a revolving credit line of up to $10.0 million. The Amendment extended the maturity date of the revolving credit line under the Credit Agreement to November 12, 2025 and also increased the interest rate to be calculated at a
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Niagen Bioscience, Inc. amended Amendment to Business Financing Agreement with Western Alliance Bank valued at Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate (effective 2023-12-08).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Western Alliance Bank
- Value
- Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate
- Effective
- 2023-12-08
Exact text from the filing
On December 8, 2023, ChromaDex Corporation (the “Company”), and the Company’s wholly owned subsidiaries, ChromaDex, Inc., a California corporation, and ChromaDex Analytics, Inc., a Nevada corporation (together with the Company, the “Borrowers”) entered into an amendment (the “Amendment”) to the business financing agreement (as amended, the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”).
View on SEC.gov